DDInter1086 DDInter1376
An alkylating agent of value against both hematologic malignancies and solid tumors.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Lomustine {u} (Compound) treats {v} (Disease) brain cancer
Lomustine {u} (Compound) binds {v} (Gene) CYP3A4
Lomustine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Lomustine {u} (Compound) causes {v} (Side Effect) Visual impairment
Lomustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Lomustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Lomustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Filgrastim
Lomustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Lomustine {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Lomustine {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Lomustine (Compound) treats brain cancer (Disease)
Lomustine (Compound) binds CYP3A4 (Gene)
Lomustine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Lomustine (Compound) causes Visual impairment (Side Effect)
Lomustine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Lomustine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Lomustine may lead to a major life threatening interaction when taken with Lomitapide
Lomustine may lead to a major life threatening interaction when taken with Clozapine